References
- de Totero D, Montera M, Rosso O, Clavio M, Balleari E, Foa R, et al. Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression. Hematol J 2004; 5: 152–160
- Romano C, De Fanis U, Sellitto A, Chiurazzi F, Guastafierro S, Giunta R, et al. Induction of CD95 upregulation does not render chronic lymphocytic leukemia B-cells susceptible to CD95-mediated apoptosis. Immunol Lett 2005; 97: 131–139
- Chu P, Deforce D, Pedersen I M, Kim Y, Kitada S, Reed J C, et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 3854–3859
- Hitoshi Y, Lorens J, Kitada S I, Fisher J, LaBarge M, Ring H Z, et al. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity 1998; 8: 461–471
- Pallasch C P, Schulz A, Kutsch N, Schwamb J, Hagist S, Kashkar H, et al. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood 2008; 112: 4213–4219
- Song Y, Jacob C O. The mouse cell surface protein TOSO regulates Fas/Fas ligand-induced apoptosis through its binding to Fas-associated death domain. J Biol Chem 2005; 280: 9618–9926
- Rosenwald A, Alizadeh A A, Widhopf G, Simon R, Davis R E, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639–1647
- Proto-Siqueira R, Panepucci R A, Careta F P, Lee A, Clear A, Morris K, et al. SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood 2008; 112: 394–397
- Damle R N, Temburni S, Calissano C, Yancopoulos S, Banapour T, Sison C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007; 110: 3352–3359
- Herve M, Xu K, Ng Y S, Wardemann H, Albesiano E, Messmer B T, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 2005; 115: 1636–1643
- Kater A P, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J, et al. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood 2005; 106: 1742–1748
- Lanemo Myhrinder A, Hellqvist E, Sidorova E, Soderberg A, Baxendale H, Dahle C, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008; 111: 3838–3848
- Pallasch C P, Schwamb J, Königs S, Schulz A, Debey S, Kofler D, et al. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia 2008; 22: 585–592